Imidazoline Receptor System: The Past, the Present, and the Future

咪唑啉受体 胍丁胺 莫索尼定 利门尼丁 可乐定 受体 兴奋剂 化学 药理学 立体化学 生物化学 内分泌学 医学 氨基酸 精氨酸
作者
Pascal Bousquet,Alan L. Hudson,Jesús A. Garcı́a-Sevilla,Jun‐Xu Li
出处
期刊:Pharmacological Reviews [American Society for Pharmacology and Experimental Therapeutics]
卷期号:72 (1): 50-79 被引量:88
标识
DOI:10.1124/pr.118.016311
摘要

Imidazoline receptors historically referred to a family of nonadrenergic binding sites that recognize compounds with an imidazoline moiety, although this has proven to be an oversimplification. For example, none of the proposed endogenous ligands for imidazoline receptors contain an imidazoline moiety but they are diverse in their chemical structure. Three receptor subtypes (I1, I2, and I3) have been proposed and the understanding of each has seen differing progress over the decades. I1 receptors partially mediate the central hypotensive effects of clonidine-like drugs. Moxonidine and rilmenidine have better therapeutic profiles (fewer side effects) than clonidine as antihypertensive drugs, thought to be due to their higher I1/α2-adrenoceptor selectivity. Newer I1 receptor agonists such as LNP599 [3-chloro-2-methyl-phenyl)-(4-methyl-4,5-dihydro-3H-pyrrol-2-yl)-amine hydrochloride] have little to no activity on α2-adrenoceptors and demonstrate promising therapeutic potential for hypertension and metabolic syndrome. I2 receptors associate with several distinct proteins, but the identities of these proteins remain elusive. I2 receptor agonists have demonstrated various centrally mediated effects including antinociception and neuroprotection. A new I2 receptor agonist, CR4056 [2-phenyl-6-(1H-imidazol-1yl) quinazoline], demonstrated clear analgesic activity in a recently completed phase II clinical trial and holds great promise as a novel I2 receptor–based first-in-class nonopioid analgesic. The understanding of I3 receptors is relatively limited. Existing data suggest that I3 receptors may represent a binding site at the Kir6.2-subtype ATP-sensitive potassium channels in pancreatic β-cells and may be involved in insulin secretion. Despite the elusive nature of their molecular identities, recent progress on drug discovery targeting imidazoline receptors (I1 and I2) demonstrates the exciting potential of these compounds to elicit neuroprotection and to treat various disorders such as hypertension, metabolic syndrome, and chronic pain.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
芷兰丁香完成签到,获得积分10
1秒前
科研狗发布了新的文献求助10
2秒前
lay完成签到,获得积分20
3秒前
科研通AI5应助百里采纳,获得10
4秒前
摇光完成签到,获得积分10
4秒前
顾矜应助震动的曲奇采纳,获得10
7秒前
科研通AI5应助自然采纳,获得10
9秒前
wangrblzu应助臣臣想睡觉采纳,获得10
12秒前
12秒前
村口的帅老头完成签到 ,获得积分10
12秒前
13秒前
wangwangwang完成签到,获得积分10
16秒前
毛毛发布了新的文献求助10
17秒前
18秒前
21秒前
震动的曲奇完成签到,获得积分10
22秒前
Mercury完成签到 ,获得积分10
23秒前
24秒前
向美而死完成签到,获得积分20
25秒前
27秒前
wayne完成签到,获得积分10
28秒前
chx2256120完成签到,获得积分10
29秒前
美满的砖头完成签到 ,获得积分10
29秒前
光亮妙之完成签到,获得积分10
30秒前
Warming发布了新的文献求助10
30秒前
31秒前
31秒前
阿庭应助lilililllll采纳,获得10
31秒前
烟花应助小何0404采纳,获得10
33秒前
33秒前
凌凌漆应助科研通管家采纳,获得10
33秒前
33秒前
情怀应助科研狗采纳,获得10
33秒前
小蘑菇应助科研通管家采纳,获得10
33秒前
CipherSage应助科研通管家采纳,获得10
33秒前
33秒前
34秒前
无花果应助科研通管家采纳,获得10
34秒前
酷波er应助科研通管家采纳,获得10
34秒前
科研通AI5应助科研通管家采纳,获得30
34秒前
高分求助中
Applied Survey Data Analysis (第三版, 2025) 800
Assessing and Diagnosing Young Children with Neurodevelopmental Disorders (2nd Edition) 700
The Elgar Companion to Consumer Behaviour and the Sustainable Development Goals 540
The Martian climate revisited: atmosphere and environment of a desert planet 500
Images that translate 500
Transnational East Asian Studies 400
Towards a spatial history of contemporary art in China 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3843754
求助须知:如何正确求助?哪些是违规求助? 3386113
关于积分的说明 10543746
捐赠科研通 3106834
什么是DOI,文献DOI怎么找? 1711181
邀请新用户注册赠送积分活动 823978
科研通“疑难数据库(出版商)”最低求助积分说明 774390